Evoke PharmaEVOK
13F holders, Q3 2024 (September 30)12holders
$4.77avg. 13F price*
At the end of Q3 2024, 12 institutions reported holding Evoke Pharma Inc. (EVOK) in their 13F filings. The largest holders were AIGH Capital Management LLC ($339K), Bleichroeder LP ($327K) and Nantahala Capital Management, LLC ($268K).
- Company
- Evoke Pharma Inc.
- CUSIP
- 30049G302
- Latest filing quarter
- Q3 2025
History
Number of 13F holders
Total Exit/New Position Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $56K |
| Exits | 0 | $0 |
Ownership 12 holders
| AIGH Capital Management LLC | 0.16% | No change | 70,546 | $339K |
| Bleichroeder LP | 0.09% | No change | 68,750 | $327K |
| Nantahala Capital Management, LLC | 0.02% | No change | 56,249 | $268K |
| Corsair Capital Management, L.P. | 0.01% | New | 11,667 | $56K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +30.9% | 816 | $4K |
| BlackRock, Inc. | 0.00% | — | 122 | $581 |
| UBS Group AG | 0.00% | Reduce -2.4% | 90 | $428 |
| Morgan Stanley | 0.00% | Reduce -0.8% | 31 | $148 |
| Bank of America Corp. | 0.00% | Add +334.8% | 25 | $119 |
| NewEdge Advisors, LLC | 0.00% | Reduce -1.9% | 17 | $81 |
| Citigroup Inc. | 0.00% | New | 4 | $20 |
| Danske Bank A/S | 0.00% | New | 2 | $10 |
"% of holder's portfolio" is EVOK's weight in each manager's 13F, not the share of Evoke Pharma Inc. the manager owns.